Genzyme Corp., the Cambridge biotechnology firm, said it received regulatory approval to manufacture one drug on a larger scale in Europe and to market a therapy in the United States.
Genzyme said the European Commission has approved the 4,000-liter manufacturing process of Myozyme at its facility in Geel, Belgium. The drug will be made commercially available immediately. Myozyme is currently approved to treat Pompe disease, a progressively debilitating and often fatal inherited disorder.
At $300,ooo a YEAR!!!!
Related: The Drug You Can't Afford
In a separate statement, Genzyme said the Food and Drug Administration has granted marketing approval for Synvisc-One, a product intended for the relief of pain associated with osteoarthritis of the knee.So what fatal side effects is the FDA overlooking on that one?
--more--"
